Agile Therapeutics, Inc. (AGRX)

Aug 26, 2024 - AGRX was delisted (reason: acquired by Insud Pharma)

1.510

0.00 (0.00%)

Inactive · Last trade price on Aug 26, 2024

Agile Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Operating Activities

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Jun '24 Jun 30, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019
Net Income	-15.86	-14.47	-25.41	-71.07	-51.85	-18.61
Depreciation & Amortization	0.4	0.39	1.53	2.22	0.28	0.16
Other Amortization	0.61	1.06	1.97	1.66	1.34	-
Loss (Gain) From Sale of Assets	-	-	11.12	-	-	-
Stock-Based Compensation	1.62	1.98	2.49	3.34	2.82	1.76
Other Operating Activities	2.35	-5.96	-25.12	1.5	-	-
Change in Accounts Receivable	-0.09	-0.02	-1.84	-0.67	-0.87	-
Change in Inventory	-4.06	-2.21	-0.76	-6.29	-	-
Change in Accounts Payable	13.66	7.69	-0.63	5.2	3.64	1.38
Change in Other Net Operating Assets	-0.35	1.95	0.71	-1.1	-2.67	-0.39
Operating Cash Flow	-1.71	-9.58	-35.95	-65.2	-47.31	-15.69
Operating Cash Flow Growth	-	-	-	-	-	-

Investing Activities

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Jun '24 Jun 30, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019
Capital Expenditures	-	-	-0.13	-0.27	-0.35	-0.1
Investment in Securities	-	-	-	39.73	-40.34	-
Investing Cash Flow	-	-	-0.13	39.46	-40.69	-0.1

Financing Activities

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Jun '24 Jun 30, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019
Long-Term Debt Issued	-	-	-	-	20	-
Total Debt Issued	-	-	-	-	20	-
Long-Term Debt Repaid	-	-1.35	-17.38	-	-	-
Net Debt Issued (Repaid)	-2.68	-1.35	-17.38	-	20	-
Issuance of Common Stock	4.45	8.24	35.43	30.42	49.04	42.42
Other Financing Activities	-	-	-	-	-1.06	-
Financing Cash Flow	1.77	6.89	22.18	30.42	67.99	42.42

Net Cash Flow

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Jun '24 Jun 30, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019
Net Cash Flow	0.06	-2.69	-13.9	4.68	-20.02	26.63

Free Cash Flow

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Jun '24 Jun 30, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019
Free Cash Flow	-1.71	-9.58	-36.08	-65.47	-47.66	-15.79
Free Cash Flow Growth	-	-	-	-	-	-
Free Cash Flow Margin	-7.91%	-48.88%	-331.50%	-1596.46%	-6363.68%	-
Free Cash Flow Per Share	-0.39	-4.44	-83.48	-1348.92	-1125.69	-638.74
Levered Free Cash Flow	3.95	-3.68	-23.95	-37.28	-26.4	-8.79
Unlevered Free Cash Flow	3.85	-3.86	-23.96	-36.5	-25.8	-8.79

Additional Metrics

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Jun '24 Jun 30, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019
Cash Interest Paid	0.31	0.36	1.16	2.38	2.1	-

SEC Filings: 10-K · 10-Q